Immuron Ltd — Capital/Financing Update 2017

Apr 10, 2017

==> picture [58 x 42] intentionally omitted <==

PRESS RELEASE: April 11, 2017

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735

==> picture [562 x 97] intentionally omitted <==

Immuron Provides Update on US Listing

Melbourne, Australia, 11 April 2017: Australian biopharmaceutical Company, Immuron Limited (ASX: IMC), announced yesterday that it has filed the second amendment of its form F-1 Registration Statement with the United States Securities and Exchange Commission (SEC). The amended F-1 can be found in the Edgar database located on the SEC’s website.

Listing on a U.S. national exchange is a corporate strategic priority for the company and we aim to accomplish this goal as quickly as possible. As is customary for all foreign filers, the second amendment to the Registration Statement and the company’s 1H2017 financial statements were extensively reviewed by our U.S. accountants and legal team to ensure compliance with SEC, NASDAQ and international accounting standard rules. It is expected that these extensive reviews will greatly enhance the possibility of an earlier listing.

Thomas Liquard, CEO of Immuron Limited stated:

“We are excited to be driving toward the finish line. 2017 will be a transformative year for the company given the clinical milestones that are planned before the end of CY2017. We are committed to listing our securities on a U.S. exchange to increase the visibility of our programs to U.S. investors and to the broader U.S. capital market in order to drive further long-term growth for all of our shareholders.”

As previously announced, the Company has made significant progress in strengthening the value of its NASH program, and expects the following data-driven milestones through the end of CY2017:

• NASH Phase II interim data (minimum of 80 patients) – Est. CY3Q2017

• MOA studies – Est. CY3Q2017 through CY4Q2017

  • SanyalBio mice NASH study

  • Duke University mice NASH study

• NASH Phase II Top Line results – Est. CY4Q2017

-- END --

ABN: 80 063 114 045 Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735

==> picture [562 x 97] intentionally omitted <==

COMPANY CONTACT: IMMURON INVESTOR RELATIONS: Thomas Liquard Peter Taylor Chief Executive Officer NWR Communications Ph: +61 (0)3 9824 5254 Ph: +61 (0)4 1203 6231 thomasliquard@immuron.com peter@nwrcommunications.com.au

ABOUT IMMURON:

Immuron Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735